Tag: B cell therapy

In clinical trials for non-Hodgkin's lymphoma, the median time to response was approximately 50 days (about 7 weeks) following a Rituxan infusion. However, the answer to how long does it take for a Rituxan infusion to work varies significantly depending on the treated condition, with some patients noticing improvement much later.

Over 1 million Americans are living with multiple sclerosis (MS), a chronic, unpredictable disease that affects the central nervous system. In the landscape of disease-modifying therapies (DMTs), B-cell targeting agents like Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) have become cornerstones of treatment for relapsing forms of MS. Choosing which is better, Kesimpta or Ocrevus, is a complex decision that involves weighing several factors, from the method of administration to subtle differences in clinical outcomes.

According to the American College of Rheumatology, rituximab is a drug used to treat rheumatoid arthritis that has not improved with other medications. It is a biologic that offers a different approach to managing disease activity, especially in patients with moderate to severe active disease who have not responded adequately to TNF antagonists.